Is BioXcel Therapeutics, Inc. (BTAI) a Buy, Sell, or Hold?
NASDAQ : BTAI
BioXcel Therapeutics, Inc. — News
$0.9495 USD
$0.05 (5.3%)
- Volume
- 303.96K
- Average Volume
- 923.25K
- Market Capitalization
- $29.32M
- P/E Ratio
- -0.14
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $8.08
- Year Low
- $0.74
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.62
| Source | Headline |
|---|---|
|
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Recommendation of “Hold” by Brokerages
Shares of BioXcel Therapeutics, Inc. (NASDAQ: BTAI - Get Free Report) have received an average recommendation of "Hold" from the four ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation defenseworld.net - 2026-08-03 04:16:02 |
|
What Makes BioXcel Therapeutics (BTAI) a New Buy Stock
BioXcel Therapeutics (BTAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2026-06-02 13:01:07 |
|
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
NEW HAVEN, Conn., May 28, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the presentation of new positive data from the Phase 3 SERENITY At-Home trial evaluating BXCL501 (sublingual dexmedetomidine) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 26 – 29 in Miami, FL. globenewswire.com - 2026-05-28 07:00:00 |
|
BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $1.5 per share a year ago. zacks.com - 2026-05-15 09:16:07 |
|
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer's dementia Evaluating strategic options with an advisor to maximize shareholder value and advance the commercial and development plans for IGALMI NEW HAVEN, Conn., May 15, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today provided a business update and reported financial results for the first quarter of 2026. globenewswire.com - 2026-05-15 07:00:00 |
